HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HUTCHMED (HCM) announced expanded Chinese national drug reimbursement coverage for ELUNATE and ORPATHYS, effective January 1, 2027, following contract renewal.
ELUNATE gains coverage with sintilimab for locally advanced or metastatic kidney cancer after prior VEGFR-targeted therapy failed, excluding patients who received first-line PD-1 or PD-L1 inhibitors. ORPATHYS gains coverage with osimertinib for locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer with MET amplification after progression on EGFR-targeted therapy. Coverage is also renewed for ORPATHYS in adults with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping alteration. All other previously included indications for ELUNATE, ORPATHYS and SULANDA remain covered under current multi-year agreements.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.ELUNATE reimbursement expands with sintilimab for locally advanced or metastatic renal cell carcinoma after failed VEGFR tyrosine kinase inhibitor therapy, without prior first-line PD-1 or PD-L1 inhibitor therapy.
- Moderate point. Forward-looking: it has not happened yet and may not happen.ORPATHYS reimbursement expands with osimertinib for locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer with MET amplification after progression on EGFR tyrosine kinase inhibitors.
- Minor pointORPATHYS coverage renewed for adults with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping alteration.
- Minor pointOther previously included indications remain covered for ELUNATE, ORPATHYS and SULANDA under current multi-year agreements.
Negative
- None.
Key Figures
- Updated NRDL effective date
- January 1, 2027
- Updated National Reimbursement Drug List
Historical Context
-
European and Japanese review accepted for ORPATHYS plus TAGRISSO in post-EGFR-targeted lung cancer.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
vegfr medical
tki medical
pd-1 medical
pd-l1 medical
nsclc medical
met amplification medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2027 will continue to include ELUNATE®, ORPATHYS® and SULANDA®. This update reflects expanded coverage for new indications, renewed agreements for existing indications, as well as continued inclusion under current multi-year agreements.
Newly Included and Renewed Indications in the Updated NRDL:
- ELUNATE® (fruquintinib) is newly included for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor (“VEGFR”) tyrosine kinase inhibitors (“TKI”) therapy and have not received programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor therapy in the first-line setting, in combination with sintilimab injection.
- ORPATHYS® (savolitinib) is newly included for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-squamous non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR-TKI therapy, in combination with osimertinib. It is also renewed for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration.
In addition to the above updates, the NRDL maintains coverage for all other previously included indications for ELUNATE®, ORPATHYS® and SULANDA® under their current multi-year agreement.
The government in China has placed great importance on improving the affordability of drug treatments for the public. As of end of 2025, 1.33 billion people in China had basic medical insurance coverage, representing around
About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three VEGFR -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.
About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®.
About Surufatinib
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA®. HUTCHMED currently retains all rights to surufatinib worldwide.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations for the commercialization of fruquintinib, savolitinib and surufatinib in China, the potential benefits and further clinical development of fruquintinib, savolitinib and surufatinib, its expectations as to whether further studies would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the commercial acceptance of fruquintinib, savolitinib and surufatinib, the impact of the inclusion of fruquintinib, savolitinib and surufatinib on the NRDL on sales of the drug and its pricing, clinical trial enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of fruquintinib, savolitinib and surufatinib to obtain regulatory approval for a targeted indication in different jurisdictions and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab or osimertinib as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
CONTACTS
| Investor Enquiries | +852 2121 8200 /ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 /HUTCHMED@fticonsulting.com |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) /HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Duncan Monteith / Ramin Naji | +44 20 7545 8000 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does HUTCHMED's expanded ELUNATE and ORPATHYS reimbursement coverage take effect?
The updated National Reimbursement Drug List takes effect on January 1, 2027. It adds indications for ELUNATE and ORPATHYS while maintaining coverage for all other previously included indications for those medicines and SULANDA.
Does Chinese national reimbursement eliminate patient copayments for HUTCHMED's cancer medicines?
Category B medicines, including novel oncology medicines, require patient copayments. The amount varies depending on the patient's province or type of National Healthcare Security Administration insurance scheme enrollment.